Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside
I'm LongbridgeAI, I can summarize articles.Kura Oncology's 12-month price target was raised to $32, implying a 222% upside from the Aug. 12 close. The average analyst estimate increased slightly to $31.83, with forecasts ranging from $15 to $76. Consensus remains 'Buy' among 15 covering analysts.
- According to estimates from 12 analysts, Kura Oncology, Inc. stock's average price target has risen from $31.17 to $31.83, with forecasts ranging from $15 to $76 per share
- Based on the Aug. 12 closing price, the updated target implies approximately 220% potential upside
- Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Kura Oncology, Inc. on the , and track all previous and future analyst recommendations for Kura Oncology, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.